Three top criticisms against CMS’ overall hospital star ratingsStakeholders say CMS’ hospital overall star ratings are biased and can unfairly damage the reputations of good hospitals.
Entresto may prevent death in some heart failure patientsTimely and broad use of Entresto could prevent or postpone more than 28,000 US deaths per year among HFrEF patients, according to research in JAMA Cardiology.
T2DM and CVD: Monitoring by pharmacists empowers patientsType 2 diabetes is associated with a two- to four-fold increase in the risk of CVD. Pharmacists can monitor and manage the risk factors.
A low-fat, plant-based diet may help obese children lower heart disease riskA low-fat plant-based vegan diet may help obese children lower their risk of heart disease, finds a new study from Cleveland Clinic.
[BLOG]: AHA Scientific Sessions 2014: Where do the PCSK9s fit in the post-IMPROVE-IT world? A “modest” proposalThis year, the American Heart Association (AHA) Scientific Sessions were held in Chicago, Illinois, from November 15 to 19. Of all of the late-breaking clinical trials presented at AHA 2014, the IMPROVE-IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial) study of Merck’s low-density lipoprotein cholesterol (LDL-C)-reducing drugs—the statin, Zocor (simvastatin), and the fixed-dose combination, Vytorin (ezetimibe/simvastatin)—stole the show.
AHA: Rivaroxaban linked to fewer hospitalization days compared to warfarin in NVAF patientsOnce-daily rivaroxaban (Xartelto, Janssen) is associated with significantly fewer hospitalization days and outpatient visits compared to warfarin in patients with nonvalvular atrial fibrillation (NVAF), according to data presented at the American Heart Association (AHA) 2014 Scientific Sessions in Chicago.
AHA issues stroke guidelines for womenFor the first time, guidelines have been developed for preventing stroke in women.
AMA says the physician exodus to hospitals overratedRecent reports claiming that physicians are moving swiftly away from private practices into hospital employment are exaggerated, according to a report released by the American Medical Association (AMA).
When it comes to safe and reliable biological medicines, manufacturing mattersManaged care and hospital decision-makers should consider that biological drugs are different from traditional drugs in terms of their complexity and there is potential for problems to arise when manufacturing is not strictly controlled. Furthermore, biological medicines are more difficult to characterize, produce, and reproduce than most traditional pharmaceuticals. This, in turn, can affect the medicine’s quality, safety, or efficacy, and can ultimately impact the reliability of supply, according to a presentation at the Hematology/Oncology Pharmacy Association’s annual conference in Los Angeles, in March.
AMCP seeks quality plan for exchangesQuality rating processes will begin in 2016 for insurance exchanges, and iindustry groups recommend using current measures